<DOC>
	<DOCNO>NCT02423083</DOCNO>
	<brief_summary>Background : - People multiple sclerosis ( MS ) get lesion brain spinal cord . These cause neurological symptom sometimes disability . Researchers want see blood pressure drug call guanabenz repair lesion help people MS . Objective : - To see guanabenz safe well tolerated people MS . Eligibility : - People 18 55 year old MS take glatiramer acetate past year . Design : - Participants screen separate protocol . For 2 month , examine magnetic resonance imaging ( MRI ) scan . This decide Stable Active MS study group . - The study last 5 month . There 11 visit , 5 overnight . - Visit 1 : overnight stay clinic : - Medical history physical exam . - Health questionnaire - Bladder ultrasound scan - Brain MRI - Electrocardiogram ( EKG ) measure heart electrical activity - Blood drawn intravenous ( IV ) line . - Participants may test strength , muscle tone , movement . - They get first dose study drug , tablet take day . - Participants take study drug home keep medicine diary . - The dose slowly increase . Each time , participant stay overnight clinic . They physical exam , EKG , MRI , IV blood draw . - Visit 6 : Participants physical exam , MRI , blood drawn . They get schedule slowly low drug dose stop take guanabenz . - Participants 2 final visit . They physical exam , EKG , MRI , IV blood draw .</brief_summary>
	<brief_title>Oral Guanabenz Multiple Sclerosis</brief_title>
	<detailed_description>OBJECTIVE : This Phase 1 clinical study aim determine whether therapeutically adequate dosage guanabenz safe well tolerated patient multiple sclerosis ( MS ) . It provide pharmacokinetic data important determination optimal dosing schedule possible future Phase 2 study . STUDY POPULATION : Six patient , age 18-55 inclusive , diagnosis definite multiple sclerosis 2010 Revised McDonald Diagnostic Criteria ( Polman et al , 2010 ) enrol . All patient treatment glatiramer acetate , Food Drug Administration ( FDA ) approve disease-modifying therapy , minimum year . Four patient clinically stable clinical relapse precede year evidence active inflammation MRI 2-month screening period ; 2 patient select base evidence on-going , active inflammation see MRI screening period . DESIGN : In open-label , single site , dose escalation study , maximum tolerate dose ( MTD ) guanabenz MS patient determine . Patients screen participation exist MS natural history study 89-N-0045 . Sequential patient enrollment space least 6 week apart . Five study drug dos explore : 4mg , 8mg , 16mg , 32mg 64mg . Dose escalation ensue precede dose tolerate , define patient-reported outcome objective clinical imaging assessment . Patients maintain low dos ( 4mg-16mg ) 14 day high dos ( 32 64mg ) 28 day . OUTCOMES : The primary outcome MTD , define maximum dose produce dose-limiting toxicity ( DLT ) 2 6 participant . Secondary outcome include patient-reported outcome , objective clinical imaging assessment 32mg 64mg , pharmacokinetics .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Guanabenz</mesh_term>
	<criteria>INCLUSION CRITERIA : MS define 2010 Revised McDonald MS Diagnostic Criteria ( 19 ) Age 1855 , inclusive , time first screen baseline visit EDSS 1.0 6 , inclusive , time first screen baseline visit Able provide inform consent Willing able participate aspect trial design followup Undergoing treatment glatiramer acetate period least 1 year prior enrollment study For female patient , agree commit use reliable/accepted method birth control ( i.e . hormonal contraception , include birth control pill , inject hormone , vaginal ring ; intrauterine device ; barrier method spermicide , include diaphragm condom ; surgical sterilization , include hysterectomy , tubal ligation , vasectomy ) duration study ADDITIONAL INCLUSION CRITERION FOR ACTIVE MS COHORT Development new T2 hyperintense contrast enhance lesion MRI screen phase , 3 lesion single scan EXCLUSION CRITERIA : Alternative diagnosis well explain neurological disability MRI finding Clinically significant medical condition , best judgment investigator , may expose patient undue risk harm prevent patient complete study ( example include , limited , cerebrovascular disease , substance abuse , ischemic cardiomyopathy , clot disorder , brittle diabetes , neurodegenerative disorder ) Undergoing treatment medication may interact guanabenz , include antihypertensive agent and/or agent lead increase catecholamine ( tricyclic antidepressant monoamine oxidase inhibitor ) Medical contraindication MRI Determination , best judgment investigator , need treat prospective participant steroid management MS screen period Pregnant breastfeed woman Abnormal screening/baseline blood test exceed limit define : A ) Serum alanine transaminase aspartate transaminase level great 3 time upper limit normal value B ) Total white blood cell count &lt; 3000/mm3 C ) Platelet count &lt; 85000/mm3 D ) Serum creatinine level &gt; 2.0 mg/dl eGFR ( estimate glomerular filtration rate ) &lt; 60 ADDITIONAL EXCLUSION CRITERIA FOR STABLE MS COHORT Evidence 1 clearly document MS relapse within last 1 year Development 2 lesion per year relative MRI perform least one year first screen MRI ( prior MRI outside MRI ) Development new T2 hyperintense contrastenhancing lesion MRI screen phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 14, 2017</verification_date>
	<keyword>Neuroprotection</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Safety Tolerability</keyword>
</DOC>